Vertebral fractures lead me down a new path on my health journey

redaccionmedica.com

Factuality

Ownership

The National Center for Oncological Research (CNIO) has made public the first fruits of D-BIOMARK, a clinical trial against breast cancer promoted by the Institut Català d’Oncologia (ICO) that has analyzed the possible antitumor role of denosumab, a drug already used in the prevention of osteoporosis and bone lesions derived from metastases. Denosumab acts by inhibition of the RANK route, a molecular pathway highly studied in Oncology due to its…

Salud a Diario

Factuality

Ownership

The drug Denosumab acts by inhibition of the RANK pathway, a molecular pathway highly studied in oncology due to its relationship to tumour proliferation and progression, especially in breast cancer. Now, according to the early results of the trial published in Breast Cancer Research, denosumab could enhance the antitumor immune response, increasing the number of immune cells infiltrating the tumor to fight cancer. The research is based on promi…

CNIO

Factuality

Ownership

The collaboration between science and society is essential for scientific advancement, especially in the healthcare and biomedical field, where basic researchers, clinicians and patients participate. This is demonstrated by the first fruits of D-BIOMARK, a clinical trial against breast cancer promoted by the Institut Català d’Oncologia (ICO) that has analyzed the possible antitumor role of denosumab, a drug already used in the prevention of oste…

El Punt Avui

Factuality

Ownership

This is the preliminary result of a clinical trial led by researchers from the ICO, the Bellvitge Biomedical Research Institute and the National Center for Oncological Research. The work determines that denosumab does not reduce the proliferation of cancer cells but stimulates the antitumor immune response.